Optimer Pharmaceuticals
New developments from Optimer Pharmaceuticals described
Published in Medicine and Law Weekly, June 22nd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Optimer Pharmaceuticals.
Report 1: Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today reported that the U.S. Food and Drug Administration has agreed with the recommendation of the independent Data Safety Monitoring Board (DSMB) to advance Difimicin (OPT-80/PAR101) into Phase 3 clinical studies.
The DSMB reviewed the Phase 2b data and stated in their written report, "No safety issues were identified precluding continuation of the study into the phase 3 portion as written in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
More Articles from Medicine and Law Weekly
- Alcoholism Therapy
Study findings from Johns Hopkins University provide new insights into alcoholism therapy - Clinical Trial Research
Research from University of Birmingham in the area of clinical trial research described - Epidemiology
Researchers at Mayo Clinic, Division of General Internal Medicine target epidemiology - Health Policy
New health policy study results from Taipei Medical University described - Health Policy
New health policy study results reported from University of Toronto, Joint Center for Bioethics - Health Policy
Research from Institute of Public Health Research, Research Department reveals new findings on health policy - More from this issue of Medicine and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
